Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Adenocarcinoma, squamous cell carcinoma, and large cell are among the several subtypes of NSCLC, classified by the type of cells that are affected.Compared to the other major kind of lung cancer, ...

While non-small cell lung cancer can’t always be prevented, there still are steps you can take to lower your risk. This starts by understanding the habits that increase your chances of ...

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early compared to other cancers and can quickly develop resistance to chemotherapy — ...

Lung cancer, the second-most common cancer in the U.S., is often associated with smoking — but even those who have never had ...

This trial involved 290 adults (149 males and 141 females), all of whom had ALK-positive non-small-cell lung cancer who had not been treated with an ALK-targeted medicine.

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to ...

How Does Imfinzi Work for Non-Small-Cell Lung Cancer? Imfinzi is a type of immunotherapy known as a checkpoint inhibitor. It helps your immune system fight cancer by blocking a checkpoint protein ...

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it ...